Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

24 Dec 2021

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world... Read more

OrganOx receives FDA approval for metra device

20 Dec 2021

OrganOx receives FDA approval for metra device OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system. The OrganOx metra is a fully automated NMP device for the preservation and transport of donor livers destined for transplantation. The marketing approval includes both livers from... Read more

Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer

10 Nov 2021

Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology, today announces the appointment of Tanya E. Borsuk, Ph.D., as its Chief Business Officer. Tanya brings 15 years of strategic and scientific expertise across business development and corporate strategy. At Sitryx, Tanya will join the... Read more

Acquisition of ATDBio by Biotage AB to provide platform for further growth

20 Oct 2021

Acquisition of ATDBio by Biotage AB to provide platform for further growth Founders look forward to continued focus on customers and innovation Oxford and Southampton, UK, October 20 2021 – ATDBio, a leader in complex oligonucleotide synthesis, is pleased to announce that it has been acquired by the Swedish life sciences company Biotage AB1 for approximately £45m in cash and shares. The acquisition, which provides Biotage with expertise in... Read more

Exscientia Announces Pricing of $304.7m Upsized IPO & $160m Concurrent Private Placements

30 Sep 2021

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS,... Read more

News